No connection

Search Results

HYPR vs MRK

HYPR
Hyperfine, Inc.
NEUTRAL
Price
$1.21
Market Cap
$119.2M
Sector
Healthcare
AI Confidence
85%
MRK
Merck & Co., Inc.
NEUTRAL
Price
$121.25
Market Cap
$299.79B
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
HYPR
--
MRK
16.66
Forward P/E
HYPR
-3.67
MRK
12.42
P/B Ratio
HYPR
2.87
MRK
5.7
P/S Ratio
HYPR
8.79
MRK
4.61
EV/EBITDA
HYPR
-2.33
MRK
11.46

Profitability

Gross Margin
HYPR
49.79%
MRK
77.21%
Operating Margin
HYPR
-144.87%
MRK
32.77%
Profit Margin
HYPR
-262.29%
MRK
28.08%
ROE
HYPR
-79.01%
MRK
36.88%
ROA
HYPR
-40.61%
MRK
12.04%

Growth

Revenue Growth
HYPR
128.0%
MRK
5.0%
Earnings Growth
HYPR
--
MRK
-19.3%

Financial Health

Debt/Equity
HYPR
0.01
MRK
0.96
Current Ratio
HYPR
4.34
MRK
1.54
Quick Ratio
HYPR
3.56
MRK
0.96

Dividends

Dividend Yield
HYPR
--
MRK
2.83%
Payout Ratio
HYPR
0.0%
MRK
45.05%

AI Verdict

HYPR NEUTRAL

HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.

Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
MRK NEUTRAL

MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (28.1% margin)
Strong ROE of 36.9%
Risks
Premium vs Graham Number ($59.01)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

HYPR vs MRK: Head-to-Head Comparison

This page compares Hyperfine, Inc. (HYPR) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile